Needham & Company LLC Reiterates Buy Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Sarepta Therapeutics (NASDAQ:SRPT)‘s stock had its “buy” rating reiterated by investment analysts at Needham & Company LLC in a research report issued to clients and investors on Thursday,Benzinga reports. They presently have a $202.00 target price on the biotechnology company’s stock. Needham & Company LLC’s target price would suggest a potential upside of 89.23% from the company’s current price.

Several other equities research analysts have also commented on the stock. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Sarepta Therapeutics in a research note on Tuesday, February 11th. They issued a “hold” rating and a $136.00 price target on the stock. StockNews.com downgraded shares of Sarepta Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, November 20th. Evercore ISI cut their target price on shares of Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating for the company in a research report on Thursday, November 7th. Cantor Fitzgerald upgraded shares of Sarepta Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $152.00 to $167.00 in a report on Thursday, November 7th. Finally, Robert W. Baird decreased their price target on shares of Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating on the stock in a research report on Thursday, November 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Sarepta Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.52.

Sarepta Therapeutics Stock Up 3.6 %

Shares of Sarepta Therapeutics stock opened at $106.75 on Thursday. The company has a fifty day moving average price of $115.89 and a 200 day moving average price of $122.61. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. Sarepta Therapeutics has a twelve month low of $101.00 and a twelve month high of $173.25. The stock has a market cap of $10.20 billion, a price-to-earnings ratio of 85.40 and a beta of 0.75.

Insider Transactions at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the company’s stock in a transaction on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now owns 5,880 shares of the company’s stock, valued at $738,234. This represents a 21.77 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the company’s stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at $2,851,345.60. This trade represents a 31.49 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by insiders.

Hedge Funds Weigh In On Sarepta Therapeutics

Hedge funds and other institutional investors have recently made changes to their positions in the company. CIBC Asset Management Inc lifted its stake in shares of Sarepta Therapeutics by 3.3% during the 3rd quarter. CIBC Asset Management Inc now owns 2,712 shares of the biotechnology company’s stock worth $339,000 after purchasing an additional 86 shares during the last quarter. Louisiana State Employees Retirement System lifted its stake in shares of Sarepta Therapeutics by 0.4% during the 4th quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock worth $3,222,000 after purchasing an additional 100 shares during the last quarter. EP Wealth Advisors LLC lifted its stake in shares of Sarepta Therapeutics by 2.2% during the 4th quarter. EP Wealth Advisors LLC now owns 4,988 shares of the biotechnology company’s stock worth $606,000 after purchasing an additional 105 shares during the last quarter. Manchester Capital Management LLC lifted its stake in shares of Sarepta Therapeutics by 86.6% during the 4th quarter. Manchester Capital Management LLC now owns 237 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 110 shares during the last quarter. Finally, UMB Bank n.a. lifted its stake in shares of Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 138 shares during the last quarter. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.